---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-276899"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:45:23.911516+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q3 net loss $27.2M; cash $673.9M; NUV-868 Phase 1b on track

## Summary
- Net loss of $27.2M ($0.12/share) vs $22.0M ($0.11/share) in Q3 2021.
- Cash, cash equivalents and marketable securities of $673.9M as of Sep 30, 2022; runway through 2028.
- R&D expenses $21.3M (incl. $1.6M restructuring and $5.7M contract termination costs).
- Phase 1 monotherapy of NUV-868 dosing; Phase 1b combo with olaparib/enzalutamide expected by end of 2022.
- DDC platform first clinical candidate nomination on track for end of 2022.

## SEC filing metadata
- accession: 0001193125-22-276899
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312522276899/0001193125-22-276899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312522276899/d410431d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-276899
- JSON: https://secwatch.observer/filing/0001193125-22-276899.json
- Plain text: https://secwatch.observer/filing/0001193125-22-276899.txt

## Key facts
- Earnings Releases
  Nuvation Bio Inc. reported the third quarter ended September 30, 2022 results: net income net loss of $27.2 million, or $(0.12) per share, EPS $(0.12) per share.
  - Period: the third quarter ended September 30, 2022
  - Net income: net loss of $27.2 million, or $(0.12) per share
  - EPS: $(0.12) per share
  - Result: reported results
  source text: For the three months ended September 30, 2022, Nuvation Bio reported a net loss of $27.2 million, or $(0.12) per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811063/000119312522276899/0001193125-22-276899-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.